Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Non-Current Assets (2021 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Non-Current Assets for 5 consecutive years, with $15.7 billion as the latest value for Q3 2025.

  • Quarterly Non-Current Assets fell 3.77% to $15.7 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $15.7 billion through Sep 2025, down 3.77% year-over-year, with the annual reading at $15.7 billion for FY2025, 3.77% down from the prior year.
  • Non-Current Assets hit $15.7 billion in Q3 2025 for Universe Pharmaceuticals, down from $16.3 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $16.3 billion in Q3 2024 to a low of $16.5 million in Q3 2023.
  • Historically, Non-Current Assets has averaged $6.4 billion across 5 years, with a median of $19.7 million in 2021.
  • Biggest five-year swings in Non-Current Assets: fell 8.76% in 2023 and later skyrocketed 99054.25% in 2024.
  • Year by year, Non-Current Assets stood at $19.7 million in 2021, then decreased by 8.29% to $18.0 million in 2022, then fell by 8.76% to $16.5 million in 2023, then surged by 99054.25% to $16.3 billion in 2024, then fell by 3.77% to $15.7 billion in 2025.
  • Business Quant data shows Non-Current Assets for UPC at $15.7 billion in Q3 2025, $16.3 billion in Q3 2024, and $16.5 million in Q3 2023.